Comparison of different promoters to improve AAV vector-mediated gene therapy for neuronopathic Gaucher disease
Human Molecular Genetics · 2024
DOI: 10.1093/hmg/ddae081 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Human Molecular Genetics, 2024. Verfasst von Giulia Massaro und 6 weiteren Autor:innen. Beteiligte Einrichtung: UCL School of Pharmacy, University College London, 29-38 Brunswick Square, London, WC1N 1AX, United Kingdom. Hauptthemen laut MEDLINE: Gaucher Disease, Genetic Vectors, Genetic Therapy, Promoter Regions, Genetic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Medical Research Council, Apollo Therapeutics, Sigrid Rausing Trust and the Jameel Education Foundation.
Abstract (Originalsprache)
Gaucher Disease (GD) is an inherited metabolic disorder caused by mutations in the GBA1 gene. It can manifest with severe neurodegeneration and visceral pathology. The most acute neuronopathic form (nGD), for which there are no curative therapeutic options, is characterised by devastating neuropathology and death during infancy. In this study, we investigated the therapeutic benefit of systemically delivered AAV9 vectors expressing the human GBA1 gene at two different doses comparing a neuronal-selective promoter with ubiquitous promoters. Our results highlight the importance of a careful evaluation of the promoter sequence used in gene delivery vectors, suggesting a neuron-targeted therapy leading to high levels of enzymatic activity in the brain but lower GCase expression in the viscera, might be the optimal therapeutic strategy for nGD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCL School of Pharmacy, University College London, 29-38 Brunswick Square, London, WC1N 1AX, United Kingdom.
- Wits/SAMRC Antiviral Gene Therapy Research Unit, Faculty of Health Sciences, University of the Witwatersrand Medical, School, 7 York Road, Parktown 2193, South Africa.
- Apollo Therapeutics, Stevenage Bioscience Catalyst, 50-60 Station Road, Cambridge, CB1 2JH, United Kingdom.
- UCL EGA Institute for Women's Health, University College London, Medical School Building, 74 Huntley Street, London, WC1E 6AU, United Kingdom.
ORCID-Profile: Giulia Massaro
Förderung
- UK Medical Research Council
- Apollo Therapeutics
- Sigrid Rausing Trust and the Jameel Education Foundation
- Institutional Strategic Support Fund
- NIHR Great Ormond Street Hospital Biomedical Research Centre
- Wellbeing of Women and Rosetrees
- GOSH Charity
- Wellcome Trust
Zitieren
APA
Massaro, G., Geard, A. F., Nelvagal, H. R., Gore, K., Clemo, N. K., Waddington, S. N., & Rahim, A. A. (2024). Comparison of different promoters to improve AAV vector-mediated gene therapy for neuronopathic Gaucher disease. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddae081
Vancouver
Massaro G, Geard AF, Nelvagal HR, Gore K, Clemo NK, Waddington SN, et al. Comparison of different promoters to improve AAV vector-mediated gene therapy for neuronopathic Gaucher disease. Human Molecular Genetics. 2024. doi:10.1093/hmg/ddae081
BibTeX
@article{Massaro2024,
author = {Massaro, Giulia and Geard, Amy F and Nelvagal, Hemanth R and Gore, Katrina and Clemo, Nadine K and Waddington, Simon N and Rahim, Ahad A},
title = {Comparison of different promoters to improve AAV vector-mediated gene therapy for neuronopathic Gaucher disease},
journal = {Human Molecular Genetics},
year = {2024},
doi = {10.1093/hmg/ddae081}
}
EUVIMED